Radiofrequency ablation for liver metastasis from gastric cancer

Chen, J; Tang, Zhe; Dong, Xin; Gao, Shunliang; Fang, He-qing; Wu, Dang; Xiang, Dong; Zhang, S

doi:10.1016/j.ejso.2013.03.023

Cited by 44 publications

(40 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we only provided liver-directed treatment for patients without extrahepatic disease. For patients with liver-only metastasis, metastasis-specific features were evaluated individually to determine the feasibility of RFA or resection [27,28]. Meanwhile, various prognostic factors, such as solitary lesion or synchronous presentation, have also been previously suggested to improve patient selection [10,26].…”

Section: Discussionmentioning

confidence: 99%

Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation

et al. 2015

View full text Add to dashboard Cite

Background Although various liver-directed treatment modalities, such as liver resection and radiofrequency ablation (RFA), have been applied to treat liver metastases from gastric cancer, optimal management of them remains controversial. In patients with liver metastasis from gastric cancer, we investigated the short-and long-term outcomes of liver resection and RFA and analyzed factors influencing survival. Methods A total of 98 gastric cancer patients with liver metastasis and no extrahepatic disease were treated by liver resection (n = 68) or RFA (n = 30). Short-and long-term outcomes were evaluated retrospectively for each of the liver-directed treatments. Results Severe complication rates did not differ between liver resection (18 %) and RFA (10 %) (p = 0.333). Only one treatment-related mortality occurred in the liver resection group. No statistically significant difference in survival was noted between the treatment groups. Median overall survival after liver resection was 24 months, with 3-year overall and progression-free survival rates of 40.6 % and 30.4 %, respectively. Median overall survival after RFA was 23 months, with 3-year overall and progression-free survival rates of 43.0 % and 37.4 %, respectively. Only the size of the metastases was shown to be an independent prognostic factor for gastric cancer patients with liver metastasis. Conclusions In select patients with liver metastasis from gastric cancer, liver resection and RFA showed satisfactory and comparable short-and long-term results. Thus, systemic chemotherapy may not be the only therapeutic option for patients with liver metastasis, and possible liver-directed treatment options for such patients should be considered on an individual basis.

show abstract

Section: Discussionmentioning

confidence: 99%

Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The third question is the role of RFA, which is performed in about 10% of metachronous LMGC patients according to our survey. In addition, limited retrospective series indicate a potential benefit of RFA for LMGC [20,21]. Taking into account that RFA is less invasive than surgery and that the treatment indication of RFA for colorectal LM has been expanding [22], treatment strategies including RFA should also be investigated.…”

Section: Number Of Lmgc Patients Treated Per Year (Question 7)mentioning

confidence: 99%

Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG

et al. 2017

View full text Add to dashboard Cite

The role of multidisciplinary treatment including surgery for liver metastases from gastric cancer (LMGC) is controversial. Studies to answer this clinical question are increasing in number, but all published data thus far are based on retrospective analyses with limited sample sizes. Thus, the European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Group (GITCG) and the Japan Clinical Oncology Group (JCOG) Stomach Cancer Study Group (SCSG) initiated a collaboration to develop an optimal treatment strategy for LMGC. Before planning a prospective study, a questionnaire was sent out to the network members of both groups in June 2016 to clarify current common practice in each region. Sixty-seven sites from 17 countries in the EORTC network and 55 sites from Japan responded. According to the survey, for patients with resectable LMGC without extrahepatic metastases, preoperative chemotherapy followed by resection of both primary (if still in place) and liver lesions was the preferred option for both the synchronous and the metachronous setting. For patients with unresectable LMGC, most of the sites recommended chemotherapy only. In this article, the detailed results of this survey are reported, shedding light on current community practice, and a joint EORTC-JCOG strategy of investigation is delineated.

show abstract

“…More recently, RF ablation was used for the treatment of liver metastases from gastric cancer after surgical treatment of the primary tumor and produced variable median survival periods ranging from 10.0 to 20.9 months with better survival outcomes in cases with single, small, and unilobar hepatic metastases (6)(7)(8). These results suggested that RF ablation could be an alternative treatment option for patients with metastases from gastric cancer that are confined to the liver.…”

mentioning

confidence: 95%

Percutaneous Radiofrequency Ablation of Hepatic Metastases from Gastric Adenocarcinoma after Gastrectomy

Lee

Kim

Won

et al. 2015

Journal of Vascular and Interventional Radiology

View full text Add to dashboard Cite

Radiofrequency ablation for liver metastasis from gastric cancer

Cited by 44 publications

References 28 publications

Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation

Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation

Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG

Percutaneous Radiofrequency Ablation of Hepatic Metastases from Gastric Adenocarcinoma after Gastrectomy

Contact Info

Product

Resources

About